HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

LH

Labcorp Holdings Inc. (S&P 500)

Healthcare — Diagnostics & Research

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Buy 1.6 / 5 17 analysts
$314.23
+$13.06 (+4.34%)
Target: $312.35 (-0.6%)
Sign in to add LH to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$25.77B
P/E Ratio (TTM)27.83
Forward P/E16.19
EPS (TTM)$11.29
Dividend Yield0.96%
Profit Margin6.66%
Revenue Growth5.80%
ROE11.05%
Debt/Equity83.41
Recommendation Buy 1.6
Analyst Target$312.35
Analysts17
Indexes S&P 500

Technical Indicators

RSI (14)82.6
Beta0.86
SMA 20$284.32
SMA 40$274.00
52-Week High$315.77
52-Week Low$244.52
50-Day Avg$269.44
200-Day Avg$267.58
Avg Volume685.4K
Volume$1.13M

Performance Analysis

NEUTRAL

LH presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($315.77), which may indicate limited upside.
- RSI at 82.6 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 5.8% year-over-year.
+ Wall Street consensus is "Buy" from 17 analysts.
- Average analyst target of $312.35 implies 0.6% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report